Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation
- 756 Downloads
Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use of current therapies. No comprehensive literature review on the relative efficacy of existing cardioversion approaches compared to newly available therapies has been conducted.
Methods and results
A systematic literature review and meta-analysis were undertaken to evaluate the efficacy of pharmacologic therapies in eliciting cardioversion within 2 and 8–24 h among patients with recent-onset, short duration AF. Eligible studies included randomized controlled trials in which cardioversion rates were evaluated in at least 2 treatment groups. Bayesian mixed-treatment comparisons estimated odds ratios (95% credible intervals) for successful cardioversion. Results within 2 h showed vernakalant IV, propafenone IV and flecainide (IV and oral) were more efficacious in pair-wise comparisons to placebo. Results were mixed in analyses comparing efficacy rates between 8 and 24 h. Few adverse events were reported, with the most common being bradycardia and hypotension.
In pair-wise comparisons of active treatment arms to one another, results suggest vernakalant IV, propafenone IV and flecainide appear to be effective in achieving rapid cardioversion in patients with short duration AF compared to other agents. Application of these findings to clinical practice need to account for the variable comorbidity profiles of patients, important determinants in the selection of appropriate therapy for individual patients. Though best practice methods were used, further research comparing treatments through direct head-to-head comparisons may be warranted to confirm these findings and further inform clinical practice.
Key wordsAtrial fibrillation Cardioversion efficacy SYSTEMATIC REVIEW Meta-analysis
- 2.Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.PubMedCrossRefGoogle Scholar
- 6.Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.Google Scholar
- 7.Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008;10:21–7.PubMedCrossRefGoogle Scholar
- 9.National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National clinical guideline for management in primary and secondary care. 2006. London, Royal College of Physicians.Google Scholar
- 12.Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126:476–86.PubMedCrossRefGoogle Scholar
- 33.Alderson P, Green S, Higgins JPT. Cochrane Collaboration Handbook 4.2.1. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd.; 2004.Google Scholar
- 36.Thomas A, O’Hara B, Ligges U, Sturtz S. Making BUGS Open. R News [ 2006 [cited 2011 Jan. 5]; 6:[12–17]Google Scholar
- 38.Pratt C, Roy D, Torp-Pedersen C, Wyse D, Toft E, Juul-Moller S et al. Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation. Am J Cardiol. 2010;106:1277–83.Google Scholar
- 43.Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RW. Amiodarone in the management of atrial fibrillation complicating myocardial infarction. Br J Clin Pract. 1986;44:155–63.Google Scholar
- 47.Tambocor™. 2007. Bishop’s Stortford, UK, Meda Pharmaceuticals, Ltd.Google Scholar
- 49.Kafkas NV, Patsilinakos SP, Mertzanos GA, Papageorgiou KI, Chaveles JI, Dagadaki OK, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol. 2007;118:321–5.PubMedCrossRefGoogle Scholar
- 53.Bash L, Avetisyan R, Davies G, Buono J, Fahrbach K, Martin A et al. Systematic Review and meta-analysis: comparative effectiveness of cardioversion treatments at 2 h for atrial fibrillation. American Heart Association Nutrition, Physical Activity, and Metabolism and Cardiovascular Disease Epidemiology and Prevention Joint Conference, Atlanta, GA. 3-24-2011.Google Scholar
- 63.Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J. 1999;20:1833–42.PubMedCrossRefGoogle Scholar
- 65.Fresco C, Proclemer A, Pavan A, Buia G, Vicentini A, Pavan D, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996;19:409–12.PubMedCrossRefGoogle Scholar
- 73.Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69–72.PubMedCrossRefGoogle Scholar